NICE-话题@MedSci

#NICE#

226篇内容 | 5145人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1289040, encodeId=cd38128904036, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE推荐帕妥珠单抗Perjeta用于治疗新的乳腺癌适应症, objectType=article, longId=160404, objectId=3b0e1604041d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b0e1604041d, replyNumber=0, likeNumber=89, createdTime=2019-02-20, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b0e1604041d, moduleTitle=英国NICE推荐帕妥珠单抗Perjeta用于治疗新的乳腺癌适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b0e1604041d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289039, encodeId=bf981289039f2, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE推荐布加替尼Alunbrig用于治疗非小细胞肺癌, objectType=article, longId=160400, objectId=625016040034, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=625016040034, replyNumber=0, likeNumber=81, createdTime=2019-02-20, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=625016040034, moduleTitle=NICE推荐布加替尼Alunbrig用于治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=625016040034)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289038, encodeId=d4ac1289038da, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=BCL-2抑制剂Venetoclax获NICE批准用于慢性淋巴细胞白血病, objectType=article, longId=158906, objectId=356b158906ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=356b158906ea, replyNumber=0, likeNumber=59, createdTime=2019-01-27, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=356b158906ea, moduleTitle=BCL-2抑制剂Venetoclax获NICE批准用于慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=356b158906ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289037, encodeId=bdf0128903e59, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE推荐BRAF激酶抑制剂与MEK抑制剂联合治疗BRAF V600突变的黑素瘤患者, objectType=article, longId=158891, objectId=8a5b15889101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a5b15889101, replyNumber=0, likeNumber=74, createdTime=2019-01-27, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a5b15889101, moduleTitle=NICE推荐BRAF激酶抑制剂与MEK抑制剂联合治疗BRAF V600突变的黑素瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a5b15889101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289036, encodeId=e39912890361e, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=2018 NICE指南：慢性阻塞性肺疾病（急性加重）的处方抗菌药应用（NG.114）, objectType=article, longId=155995, objectId=ea45155995a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea45155995a5, replyNumber=0, likeNumber=49, createdTime=2018-12-19, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea45155995a5, moduleTitle=2018 NICE指南：慢性阻塞性肺疾病（急性加重）的处方抗菌药应用（NG.114）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea45155995a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289035, encodeId=57b7128903586, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=重视痴呆的诊断和生活质量提高 ——2018 NICE《痴呆的评估和管理指南》解读, objectType=article, longId=154798, objectId=e98d154e98d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e98d154e98d4, replyNumber=0, likeNumber=25, createdTime=2018-12-02, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e98d154e98d4, moduleTitle=重视痴呆的诊断和生活质量提高 ——2018 NICE《痴呆的评估和管理指南》解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e98d154e98d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289034, encodeId=47721289034c1, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE否定了阿斯利康的PARP抑制剂Lynparza在卵巢癌维持治疗中的应用, objectType=article, longId=153276, objectId=77c61532e65e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77c61532e65e, replyNumber=0, likeNumber=63, createdTime=2018-11-13, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77c61532e65e, moduleTitle=NICE否定了阿斯利康的PARP抑制剂Lynparza在卵巢癌维持治疗中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77c61532e65e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289033, encodeId=6e721289033e0, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE拒绝将诺华的CAR-T疗法Kymriah（标价37万美元）用于治疗淋巴瘤, objectType=article, longId=149144, objectId=4fbb149144f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4fbb149144f6, replyNumber=0, likeNumber=60, createdTime=2018-09-21, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4fbb149144f6, moduleTitle=NICE拒绝将诺华的CAR-T疗法Kymriah（标价37万美元）用于治疗淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4fbb149144f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289032, encodeId=fe0b128903288, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE支持Tafinlar与Mekinist的组合治疗晚期黑色素瘤, objectType=article, longId=149047, objectId=197214904e64, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=197214904e64, replyNumber=0, likeNumber=68, createdTime=2018-09-19, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=197214904e64, moduleTitle=NICE支持Tafinlar与Mekinist的组合治疗晚期黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=197214904e64)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289031, encodeId=723112890313e, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=2018 NICE指南：胰腺炎（NG.104）, objectType=article, longId=148488, objectId=c2a9148488a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2a9148488a6, replyNumber=0, likeNumber=54, createdTime=2018-09-10, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2a9148488a6, moduleTitle=2018 NICE指南：胰腺炎（NG.104）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2a9148488a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289030, encodeId=e32812890305c, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=英国NICE拒绝了Biogen的Spinraza治疗遗传性脊髓性肌萎缩症, objectType=article, longId=146658, objectId=8dd1146658a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dd1146658a8, replyNumber=0, likeNumber=61, createdTime=2018-08-16, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dd1146658a8, moduleTitle=英国NICE拒绝了Biogen的Spinraza治疗遗传性脊髓性肌萎缩症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dd1146658a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289029, encodeId=62c31289029f8, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE改变了对辉瑞公司Besponsa的看法, objectType=article, longId=146271, objectId=147a1462e17b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=147a1462e17b, replyNumber=0, likeNumber=51, createdTime=2018-08-11, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=147a1462e17b, moduleTitle=NICE改变了对辉瑞公司Besponsa的看法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=147a1462e17b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289028, encodeId=7639128902892, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=2018 年NICE咽喉痛（急性）抗菌药物处方指南解读（二）—指南制定证据和委员会讨论意见, objectType=article, longId=145476, objectId=2dc71454e6a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dc71454e6a2, replyNumber=0, likeNumber=0, createdTime=2018-07-31, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dc71454e6a2, moduleTitle=2018 年NICE咽喉痛（急性）抗菌药物处方指南解读（二）—指南制定证据和委员会讨论意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2dc71454e6a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289027, encodeId=2139128902e09, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=2018年NICE咽喉痛（急性）抗菌药物处方指南解读（一）—抗菌药物处方选用和自我保健方案, objectType=article, longId=145203, objectId=4e2714520308, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e2714520308, replyNumber=0, likeNumber=31, createdTime=2018-07-27, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e2714520308, moduleTitle=2018年NICE咽喉痛（急性）抗菌药物处方指南解读（一）—抗菌药物处方选用和自我保健方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e2714520308)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289026, encodeId=3c471289026cb, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE拒绝Darzalex组合用于多发性骨髓瘤的前治疗, objectType=article, longId=144490, objectId=39ef144490b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39ef144490b3, replyNumber=0, likeNumber=67, createdTime=2018-07-17, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39ef144490b3, moduleTitle=NICE拒绝Darzalex组合用于多发性骨髓瘤的前治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39ef144490b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289025, encodeId=95ca1289025ed, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE支持罗氏的Alecensa, objectType=article, longId=141914, objectId=97bd14191406, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97bd14191406, replyNumber=0, likeNumber=85, createdTime=2018-06-30, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97bd14191406, moduleTitle=NICE支持罗氏的Alecensa, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97bd14191406)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289024, encodeId=d490128902482, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE掉头支持罗氏的Ocrevus治疗多发性硬化症, objectType=article, longId=141577, objectId=74621415e717, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74621415e717, replyNumber=0, likeNumber=76, createdTime=2018-06-26, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74621415e717, moduleTitle=NICE掉头支持罗氏的Ocrevus治疗多发性硬化症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74621415e717)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289023, encodeId=5b12128902368, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE认为MSD的Keytruda作为一线肺癌治疗具有成本效益, objectType=article, longId=140288, objectId=4554140288e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4554140288e6, replyNumber=0, likeNumber=76, createdTime=2018-06-09, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4554140288e6, moduleTitle=NICE认为MSD的Keytruda作为一线肺癌治疗具有成本效益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4554140288e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289022, encodeId=5e39128902271, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=NICE批准默沙东的Keytruda用于治疗膀胱癌, objectType=article, longId=136973, objectId=10a31369e301, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10a31369e301, replyNumber=0, likeNumber=70, createdTime=2018-05-03, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10a31369e301, moduleTitle=NICE批准默沙东的Keytruda用于治疗膀胱癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10a31369e301)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1289021, encodeId=86b3128902159, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, objectTitle=2018 NICE指南：学习障碍的老年人的照护和支持, objectType=article, longId=136282, objectId=16a7136282fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16a7136282fc, replyNumber=0, likeNumber=31, createdTime=2018-04-25, rootId=0, userName=fusion, userId=743b215, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16a7136282fc, moduleTitle=2018 NICE指南：学习障碍的老年人的照护和支持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16a7136282fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

NICE

2020-05-29

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE推荐帕妥珠单抗Perjeta用于治疗新的乳腺癌适应症

2019-02-20

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE推荐布加替尼Alunbrig用于治疗非小细胞肺癌

2019-02-20

fusion (审核中...)

前往app查看评论内容

#NICE#

BCL-2抑制剂Venetoclax获NICE批准用于慢性淋巴细胞白血病

2019-01-27

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE推荐BRAF激酶抑制剂与MEK抑制剂联合治疗BRAF V600突变的黑素瘤患者

2019-01-27

fusion (审核中...)

前往app查看评论内容

#NICE#

2018 NICE指南：慢性阻塞性肺疾病（急性加重）的处方抗菌药应用（NG.114）

2018-12-19

fusion (审核中...)

前往app查看评论内容

#NICE#

重视痴呆的诊断和生活质量提高 ——2018 NICE《痴呆的评估和管理指南》解读

2018-12-02

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE否定了阿斯利康的PARP抑制剂Lynparza在卵巢癌维持治疗中的应用

2018-11-13

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE拒绝将诺华的CAR-T疗法Kymriah（标价37万美元）用于治疗淋巴瘤

2018-09-21

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE支持Tafinlar与Mekinist的组合治疗晚期黑色素瘤

2018-09-19

fusion (审核中...)

前往app查看评论内容

#NICE#

2018 NICE指南：胰腺炎（NG.104）

2018-09-10

fusion (审核中...)

前往app查看评论内容

#NICE#

英国NICE拒绝了Biogen的Spinraza治疗遗传性脊髓性肌萎缩症

2018-08-16

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE改变了对辉瑞公司Besponsa的看法

2018-08-11

fusion (审核中...)

前往app查看评论内容

#NICE#

2018 年NICE咽喉痛（急性）抗菌药物处方指南解读（二）—指南制定证据和委员会讨论意见

2018-07-31

fusion (审核中...)

前往app查看评论内容

#NICE#

2018年NICE咽喉痛（急性）抗菌药物处方指南解读（一）—抗菌药物处方选用和自我保健方案

2018-07-27

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE拒绝Darzalex组合用于多发性骨髓瘤的前治疗

2018-07-17

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE支持罗氏的Alecensa

2018-06-30

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE掉头支持罗氏的Ocrevus治疗多发性硬化症

2018-06-26

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE认为MSD的Keytruda作为一线肺癌治疗具有成本效益

2018-06-09

fusion (审核中...)

前往app查看评论内容

#NICE#

NICE批准默沙东的Keytruda用于治疗膀胱癌

2018-05-03

fusion (审核中...)

前往app查看评论内容

#NICE#

2018 NICE指南：学习障碍的老年人的照护和支持

2018-04-25

科室
- - 订阅+
  - 更多科室
工具
服务